Daily Change:+10.50p (up 0.96%) as of the latest session
Renalytix Plc is a precision-medicine diagnostics company focused on improving the clinical management of chronic kidney disease. Its principal product, kidneyintelX.dkd, combines blood biomarkers, patient information and an algorithm-based assessment to identify the risk of progressive kidney-function decline in patients with diabetic kidney disease. …
Proteome Sciences PLC is a specialist provider of contract proteomics, chemoproteomics and biomarker services to pharmaceutical, biotechnology and academic customers. It applies advanced mass-spectrometry workflows to biological samples, helping clients discover drug targets, understand mechanisms of action and identify disease biomarkers. The stock’s advance …
Hikma Pharmaceuticals Plc is a multinational medicines manufacturer with operations spanning Injectables, Branded medicines and Hikma Rx. Its geographic footprint covers North America, Europe and the Middle East and North Africa. Investor sentiment improved sharply after the company delivered a solid first half, with …
Management paired that outlook with a clear signal on capital returns. The interim dividend was lifted about 15% and the board launched a $200m share buyback to be completed by the end of 2026. For a company whose recent narrative has been dominated by …
Key HighlightsOXB launched a fast-track viral vector service on 13 April 2026, compressing AAV manufacturing timelines from roughly 15 months to as little as seven, and lentiviral from 12-18 months to around nine.FY2025 results (26 March 2026) showed revenue of £170.9m (up 33% constant …
In an RNS released at 07:00 on 6 August 2026, the company said SVN-015 had advanced within NIDA's Addiction Treatment Discovery Program (ADTP) after encouraging results from an initial screening stage, clearing the way for the next tranche of non-dilutive, externally funded work. For …
Scancell Holdings (LSE:SCLP), the Oxford- and Nottingham-based cancer immunotherapy developer, has moved to solve the problem that dogs almost every clinical-stage biotech: how to pay for a pivotal trial. On 23 July 2026 the AIM-quoted group unveiled an all-share merger with Nasdaq-listed Neuphoria Therapeutics, …
Diaceutics (LSE:DXRX) used a late-July trading update to put the spotlight squarely on the number it most wants shareholders to follow. In a statement to the market on 29 July 2026, the Belfast-based precision-medicine data specialist said annual recurring revenue (ARR) had climbed 75% …
PureTech Health (LSE:PRTC) has spent 2026 converting scientific promise into balance-sheet strength, and its most recent move underscores the shift. On 2 July the London-listed, Boston-based group confirmed that Celea Therapeutics — the founded entity built around its lead antifibrotic, deupirfenidone (formerly LYT-100) — …